These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25709079)

  • 1. Care trajectories are associated with quality improvement in the treatment of patients with uncontrolled type 2 diabetes: A registry based cohort study.
    Goderis G; Van Casteren V; Declercq E; Bossuyt N; Van Den Broeke C; Vanthomme K; Moreels S; Nobels F; Mathieu C; Buntinx F
    Prim Care Diabetes; 2015 Oct; 9(5):354-61. PubMed ID: 25709079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with Prolonged Inaction in the hypoglycaemic treatment in people with non-insulin dependent Type 2 Diabetes and elevated glycated haemoglobin: A registry-based cohort study.
    Goderis G; Vaes B; Van den Akker M; Elli S; Mathieu C; Buntinx F; Henrard S
    Prim Care Diabetes; 2017 Oct; 11(5):482-489. PubMed ID: 28648964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Torffvit O; Pehrsson NG
    Prim Care Diabetes; 2015 Feb; 9(1):15-22. PubMed ID: 25175385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting.
    Digenio A; Karve S; Candrilli SD; Dalal M
    Postgrad Med; 2014 Oct; 126(6):49-59. PubMed ID: 25414934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins.
    Hasegawa Y; Hori M; Nakagami T; Harada-Shiba M; Uchigata Y
    J Clin Lipidol; 2018; 12(1):62-69.e1. PubMed ID: 29217412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes.
    Swoboda PP; Erhayiem B; Kan R; McDiarmid AK; Garg P; Musa TA; Dobson LE; Witte KK; Kearney MT; Barth JH; Ajjan R; Greenwood JP; Plein S
    Cardiovasc Diabetol; 2018 Mar; 17(1):35. PubMed ID: 29506523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
    Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
    Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficacy and safety of human glucagon-like peptide-1 analogue liraglutide in newly diagnosed type 2 diabetes with glycosylated hemoglobin A1c > 9].
    Yan L; Wang S; Chen P; Chen C; Shao Z; Xu X; Huang Q
    Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):307-12. PubMed ID: 26268058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
    Tong L; Pan C; Wang H; Bertolini M; Lew E; Meneghini LF
    Diabetes Obes Metab; 2018 Apr; 20(4):831-839. PubMed ID: 29119712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry.
    Luk AO; Li X; Zhang Y; Guo X; Jia W; Li W; Weng J; Yang W; Chan WB; Ozaki R; Tsang CC; Mukhopadhyay M; Ojha AK; Hong EG; Yoon KH; Sobrepena L; Toledo RM; Duran M; Sheu W; Q Do T; Nguyen TK; Ma RC; Kong AP; Chow CC; Tong PC; So WY; Chan JC;
    Diabet Med; 2016 Sep; 33(9):1230-9. PubMed ID: 26511783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting.
    Kesavadev J; Shankar A; Gopalakrishnan G; Jothydev S
    Diabetes Metab Syndr; 2015; 9(1):30-3. PubMed ID: 25605673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based study.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabet Med; 2017 Feb; 34(2):213-222. PubMed ID: 27279380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.
    Hughes E
    Prim Care Diabetes; 2016 Jun; 10(3):202-9. PubMed ID: 26776758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.
    Bramlage P; Gitt AK; Schneider S; Deeg E; Tschöpe D;
    BMC Cardiovasc Disord; 2014 Nov; 14():162. PubMed ID: 25410473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.
    Li CJ; Li J; Zhang QM; Lv L; Chen R; Lv CF; Yu P; Yu DM
    Cardiovasc Diabetol; 2012 Nov; 11():142. PubMed ID: 23153177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfil guideline recommended targets? A report from the EUROASPIRE III cross-sectional study.
    Gyberg V; Kotseva K; Dallongeville J; Backer GD; Mellbin L; Rydén L; Wood D; Bacquer DD;
    Eur J Prev Cardiol; 2015 Jun; 22(6):753-61. PubMed ID: 24691153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effectiveness and safety of liraglutide in clinical practice.
    Ponzani P
    Minerva Endocrinol; 2013 Mar; 38(1):103-12. PubMed ID: 23435446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries.
    Hermans MP; Brotons C; Elisaf M; Michel G; Muls E; Nobels F;
    Eur J Prev Cardiol; 2013 Dec; 20(6):1095-105. PubMed ID: 22605788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.